Prevision Medicine joins Future of Health Grant’s Spring 2026 cohort
The Zurich company was selected for Level 2 support for its functional oncology testing business.
Prevision Medicine was selected for Level 2 of the Future of Health Grant in the Spring 2026 intake announced on March 5.
The programme provides non-dilutive support, coaching and access to healthcare partners. Prevision tests living patient cancer cells against drugs and combinations, supplying functional response data to the treating oncologist.